Xtandi 40 MG tablet 120S
Ended Awarded Last action
- Contract number
- SPE2DR26FFAZ4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $12,766
Award facts
- Contract value 100% obligated
- $12,766.02 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a firm fixed-price delivery order valued at $12,766.02 to DMS Pharmaceutical Group Inc. for 120 tablets of Xtandi 40 mg, an oncology medication used in prostate cancer treatment. This delivery order, issued on January 20, 2026, represents one of numerous pharmaceutical procurements under DMS Pharmaceutical Group's broader contractual relationship with the federal government. The award carries no set-aside designation, indicating the company competed in an unrestricted procurement process. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, serves as a critical supplier within the Department of Defense's medical supply chain and has maintained SAM registration since July 2001.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency designated as contract SPE2DR, awarded in November 2025 under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative. The underlying IDC carries a $499,999,999 ceiling value and extends through December 31, 2036, comprising a 30-month base period with three 30-month option periods. The PPV-G GEN V program represents a $30.3 billion government-wide acquisition strategy designed to consolidate pharmaceutical procurement for military healthcare facilities worldwide. DMS Pharmaceutical Group's vendor profile demonstrates substantial capability in delivering an extensive portfolio of branded and generic medications, biologics, vaccines, and medical consumables to support DOD healthcare operations globally.
Quick answers
Who was awarded contract SPE2DR26FFAZ4?
SPE2DR26FFAZ4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 20, 2026.
How much is contract SPE2DR26FFAZ4 worth?
The government has obligated $12,766 on SPE2DR26FFAZ4.
Is contract SPE2DR26FFAZ4 an order under another contract?
Yes. SPE2DR26FFAZ4 is a delivery order under SPE2DR25D9225, an indefinite delivery contract.
Was contract SPE2DR26FFAZ4 competed?
The extent of competition for SPE2DR26FFAZ4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award